Pharma Update

Responsible pricing as we advance the standard of care Savings for healthcare systems and lower out-of-pocket costs for patients Key products priced below competitors in the US COLUMVI ~12% glofitamab lower price¹ vs. Epkinly Historical net price increases below CPI in the US US net price increase below inflation? US net price increase above inflation? Roche 2018 -20% lower price² 2019 vs. Eylea High Dose VABYSMO 2020 Evrysdi ~22% lower price³ risdiplam vs. Spinraza 2021 2022 ~36% HEMLIBRA emicizumab-kxwh injection for subcutaneous use lower price4 vs. Altuviiio 2023E* mg/mL -8% -4% 0% 4% 8% US Net WAPPI vs. CPI-U OCREVUSⓇ ocrelizumab FOR N ~25% lower price5 vs. Rebif No impact expected from IRA inflationary penalties 1 Annual cost of Epkinly; 2 discount based on WAC per vial; 3³ discount over 5-yrs (at max Evrysdi price); 4 discount at launch based on WAC, annualized average for prophylaxis in a patient weighing 63.4kg. Based on US label dosing, including 50 IU/kg for Altuviiio. Cost of drug can be highly variable depending on several factors including dosing schedule and disease severity.; 5 discount at launch, based on list price; 6 Genentech's annual average net price increase in the U.S., weighted by sales; 7 source: U.S. Bureau of Labor Statistics; *2023 Net WAPPI of 1.28%; CPI-U forecast of 4.36% (S&P Global Market Intelligence); WAPPI = weighted average portfolio price increase; CPI-Consumer Price Index 43

View entire presentation